Paper38142147
The potential of mRNA vaccines in cancer nanomedicine and immunotherapy.
Pan S and 4 others. Trends Immunol, 2024. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. The potential of mRNA vaccines in cancer nanomedicine and immunotherapy. Papers, record 38142147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38142147
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Cancer Vaccines | Major topic |
| Humans | |
| Nanomedicine | |
| mRNA Vaccines | |
| Immunotherapy |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 31971308, 82102767 AND U1903211 | National Natural Sciences Foundation of China | PubMed | ||
| 2023AB047 | Science and Technology Planning Project of Shihezi University | PubMed | ||
| 2019ZX09301-147 | National S&T Major Project | PubMed | ||
| 2022YFS0007 | Sichuan Science and Technology Program | PubMed |
Source PubMed
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42871871 | Oxygen-generating cryogel vaccines help overcome tumor antigen tolerance and induce durable antitumor immunity in prostate cancer. | Cell Biomater | 2026 | https://conductscience.org/library/papers/42871871 | PubMed |
| 42646699 | Advances in Therapeutic Melanoma Vaccines (2010-2025). | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42646699 | PubMed |
| 42482783 | mRNA cancer vaccines: delivery strategies, immune modulation, and clinical translation. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42482783 | PubMed |
| 41909509 | Nanomaterial-driven modulation of lipid metabolism: Novel strategies toward precision obesity treatment. | Bioact Mater | 2026 | https://conductscience.org/library/papers/41909509 | PubMed |
| 41492458 | Targeted reduction-responsive nanovehicles for photodynamic therapy-primed immunotherapy in melanoma. | J Pharm Anal | 2025 | https://conductscience.org/library/papers/41492458 | PubMed |
| 41377933 | mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics. | Cancer Innov | 2025 | https://conductscience.org/library/papers/41377933 | PubMed |
| 41366793 | Convergence of mRNA technology and chimeric antigen receptor therapy: targeted technology optimizing targeted therapy. | J Transl Med | 2025 | https://conductscience.org/library/papers/41366793 | PubMed |
| 41179708 | mRNA Vaccines: Current Applications and Future Directions. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/41179708 | PubMed |
| 40352591 | Expanding horizons of cancer immunotherapy: hopes and hurdles. | Front Oncol | 2025 | https://conductscience.org/library/papers/40352591 | PubMed |
| 40137165 | Nanomedicines Targeting Metabolic Pathways in the Tumor Microenvironment: Future Perspectives and the Role of AI. | Metabolites | 2025 | https://conductscience.org/library/papers/40137165 | PubMed |
| 39762875 | mRNA vaccines in the context of cancer treatment: from concept to application. | J Transl Med | 2025 | https://conductscience.org/library/papers/39762875 | PubMed |
| 39543114 | Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/39543114 | PubMed |
| 39534380 | Nasal mRNA Nanovaccine with Key Activators of Dendritic and MAIT Cells for Effective Against Lung Tumor Metastasis in Mice Model. | Int J Nanomedicine | 2024 | https://conductscience.org/library/papers/39534380 | PubMed |
| 39242807 | A translational framework to DELIVER nanomedicines to the clinic. | Nat Nanotechnol | 2024 | https://conductscience.org/library/papers/39242807 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38142147
GET https://conductscience.org/api/papers/v1/38142147/authors